Replies to post #247350 on Avid Bioservices Inc (CDMO)

[InternetForumUser]

Piper Jaffray has been removed from Peregrine's Website, so that original posts about them dropping coverage was correct.

[biopharm]

Analyst Coverage
Firm Analyst

NOBLE Life Science Partners Rahul Jasuja, Ph.D.
FBR & Co. Thomas Yip
ROTH Capital Partners Joseph Pantginis, Ph.D.

Rahul is on the BOD of Pelican Therapeutics.

Summary

Rahul R. Jasuja, PhD.
Dr. Jasuja is currently Managing Director, Biotechnology Research at Noble Life Science Partners (NLSP). He is also member of the Board of Directors at Pelican Therapeutics, developing a novel T-cell co-stimulator for immuno-oncology. He is passionate about innovation in immunology/immunotherapy drug development. Prior to NLSP, he was Vice President Corporate Development at Idera Pharmaceuticals, focused on developing Toll-like receptor based immune-modulators. Previously Dr. Jasuja held progressively senior positions in the biotechnology capital markets at Techvest, Rodman & Renshaw, and MDB Capital Group. He brings more than 20 years experience in the biotechnology field encompassing corporate/business development, technology due-diligence, equity research and academic research. He has participated in numerous therapeutic drug development investor/business panels, authored and co-authored several biotechnology business white papers. He obtained his B.Sc. in Microbiology & Biochemistry from the University of Bombay and his M.S. in Microbiology from the University of Montana, Missoula, where is studied the role of bacterial cell wall immunodulators on arachidonic acid metabolism and inflammatory pathways in macrophages. Dr. Jasuja received his Ph.D. in Immunology from Tufts University School of Medicine in Boston where he explored aspects T-cell activation and the subsequent regulation of adhesion receptors in the immune response. Dr. Jasuja conducted doctoral and post-doctoral research at Harvard Medical School, in the Dept of Hematology & Oncology at Beth Israel Deaconess Medical Center
..
..

Experience

Managing Director, Biotechnology Research
Noble Life Science Partners
August 2011 – Present (4 years 6 months)New York, NY and Boca Raton, FL

Comprehensive research driven approach applied to help emerging drug development companies in the capital markets; Established a Scientific Advisory Board with ex-Big Pharma senior drug development and business development executives to enhance efforts in scientific due-diligence, business development and advisory for emerging therapeutic drug development companies - private and public (Noble Life Science Partners is a business unit of Noble Capital Markets, created to focus and specialize in life sciences)

Member Board of Directors
Pelican Therapeutics
May 2014 – Present (1 year 9 months)Boca Raton Florida

Instrumental in the scouting diligence of a novel immuno-oncology asset TNFRSF25 at Pelican Therapeutics; Active in the strategic, corporate, investment, and drug development progress of Pelican. TNFRSF25 is a novel and distinct co-stimulator on T-cells that may have advantages over other co-stimulators (GITR, 4-1BB, OX40) that are in development for oncology; TNFRSF is activated only in the presence of cognate antigen.

The company was founded in 2011 based on technology developed by Dr. Eckhard R. Podack and
Dr. Taylor H. Schreiber at the University of Miami.

Company website: www.pelicantherapeutics.com

https://www.linkedin.com/in/rahul-r-jasuja-5157436

----------------------------------------------------------

BOARD OF DIRECTORS

Taylor H. Schreiber, M.D., Ph.D., Scientific Founder

Dr. Taylor H. Schreiber Is a Director of Pelican Therapeutics, Inc. , and Chairman of its Scientific Advisory Board.

Dr. Schreiber is a founder and the co-inventor of the TNFRSF25 agonist technology together with Dr. Eckhard R. Podack. Dr. Schreiber received his Ph.D. degree from the Sheila and David Fuente Program in Cancer Biology as well as his M.D. degree at the University of Miami Miller School of Medicine. Following his degrees, Dr. Schreiber completed a post-doctoral fellowship with Dr. Podack studying the immunobiology of TNFRSF25 from 2010-2012. Dr. Schreiber received the best overall research award at the National Student Research Forum in 2008 and was nominated as a Future Leader in Cancer Research by the American Association for Cancer Research in 2011. Dr. Schreiber is an emerging expert in the field of tumor immunology and TNFRSF25 biology and serves as the Vice President of Research & Development for Heat Biologics (HTBX). Dr. Schreiber received his B.A. in Biology from Bucknell University.

Josiah C. Hornblower, Chairman, Chief Executive Officer

Josiah is a co-founder of Pelican Therapeutics, and at inception was the company's acting CEO. Josiah is a private investor focused on companies in biotechnology and financial services. Since 2008, Josiah has been a Managing Member of Blue Pine Partners, LLC, an investment and advisory firm that he founded in the community bank sector. Since 2010, Josiah has been a managing member of Brightline Ventures, the lead outside investor in Pelican Therapeutics. From 2004 to 2008, Josiah was a principal of Resource Financial Institutions Group, Inc. (RFIG), a manager of private equity funds solely devoted to investing in early stage commercial banks. During that period, he served on the Board of Directors of Pacific Enterprise Bancorp, an Orange County, California-based commercial bank. Before joining RFIG, Josiah worked as an equity analyst at Gray Seifert and Co., an investment management firm specializing in financial services, and at Barrett Associates, Inc. At both firms, he researched and invested in regional banks and financial technology companies. Josiah is currently a director of Capital Pacific Bank, based in Portland, Oregon. Josiah graduated with a Bachelor of Arts degree from Trinity College and was a member of Phi Beta Kappa. He resides in Austin, Texas.

Edward Smith

Ed Smith is the Managing Partner of Aristar Capital Management, LLC, a New York-based investment firm. On January 8, 2015, Mr. Smith was appointed Chief Executive Officer of Z Trim Holdings Inc. (OTC:ZTHO), an AgriTech company that has developed new, products and processes to transform biomass for uses in the food and industrial markets. From April 2005 through December 2014, Mr. Smith was the Managing Partner of Brightline Capital Management, LLC ("BCM"), a New York-based investment firm founded in 2005. Prior to founding BCM, Mr. Smith worked at Gracie Capital from 2004-2005, GTCR Golder Rauner from 1999-2001 and Credit Suisse First Boston from 1997-1999. Mr. Smith holds a Bachelor of Arts in Social Studies from Harvard College and a Masters in Business Administration from Harvard Business School. Mr. Smith is also a director of Z Trim Holdings Inc. and Heat Biologics, Inc. (NASDAQ: HTBX), a development stage biopharmaceutical company that focuses on the development and commercialization of novel allogeneic off-the-shelf cellular therapeutic vaccines for a range of cancers and infectious diseases.

Jeffrey Wolf

Jeffrey Wolf is a co-founder of Pelican Therapeutics. He was formerly the founder and managing director at Seed-One Ventures, a firm focused on the systematic formation and management of new biomedical companies based upon novel research breakthroughs.

Throughout his career Mr. Wolf has created life science startup companies and actively supported the growth of these companies. Mr. Wolf’s start-ups include Heat Biologics (NASDAQ: HTBX) an immunotherapy company that he founded and serves as CEO, Avigen (co-founder and director), a NASDAQ-listed gene therapy company; TyRxPharma (co-founder and Chairman) which was focused on the development of novel bio-compatible polymers and recently sold to Medtronic; EluSys Therapeutics (founder and CEO), focused on the development of novel antibodies against infectious diseases and GenerationOne (founder and CEO), focused on mobile-based healthcare solutions.
Mr. Wolf received his M.B.A. from Stanford Business School, his J.D. from New York University School of Law and his B.A. from the University of Chicago, where he graduated with honors in Economics.

http://www.pelicantherapeutics.com/aboutus.php

-------------------------------------------------------

I still wonder what Pelican must think when Rahul shows up on Peregrines conference call saying there is "no other" company out there with such a unique drug with Bavituximab's MOA, though he does say Pelican's pipeline has advantages over a few others, such as GITR, 4-1BB, OX40 but does not dare place Peregrine's Bavituximab in this category. Wonder if there is a collaboration going on here with Pelican <> Peregrine. The bird duo

http://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=265742077

----------------------------------------------------

Falcon vs Pelican, Peregrine must place everyone on watch that flies near her and metaphorically, Peregrine keeping a close eye on their nest now.

http://10000birds.com/peregrine-falcon-vs-brown-pelican.htm